Format

Send to

Choose Destination
J Drugs Dermatol. 2003 Aug;2(4):375-7.

Adalimumab (HUMIRA): a review.

Author information

1
Columbia University Medical School, St.-Lukes Roosevelt Hospital Center, 1090 Amsterdam Ave., Suite 11C, New York, NY 10025, USA. NSS32@columbia.edu

Abstract

Adalimumab (HUMIRA, Abbott Laboratories) is a new fully human TNF-alpha monoclonal antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions, including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results, and related discussion.

PMID:
12884458
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center